SCHEMBL481156

SCHEMBL481156

CCCc1c(C(S)c2cccc(Cc3cccc(C(=O)OC)c3)c2)ccc(C(C)=O)c1O

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 2/20 0.41
CYP4A11 Q02928 2/20 0.41
SLC7A5 Q01650 1/20 0.40
CYSLTR1 Q9Y271 4/20 0.39
CYSLTR2 Q9NS75 3/20 0.39
LOXL2 Q9Y4K0 1/20 0.39
GRM2 Q14416 2/20 0.37
FOLH1 Q04609 1/20 0.36
DHFR P00374 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
ATM Q13315 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
PPARG P37231 3/20 0.36
PPARA Q07869 3/20 0.36
PPARD Q03181 1/20 0.36
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL480793 0.77 CYSLTR1 (0.42) CYP4F2CYP4A11SLC7A5CYSLTR1CYSLTR2
SCHEMBL481157 0.77 NPC1 (0.43) CYP4F2CYP4A11SLC7A5CYSLTR1CYSLTR2
SCHEMBL10740766 0.75 CYSLTR1 (0.60) CYSLTR1CYSLTR2GRM2PPARGPPARA
SCHEMBL10958654 0.74 CYSLTR1 (0.46) CYSLTR1CYSLTR2GRM2MEN1KMT2A
SCHEMBL2892010 0.70 CYSLTR1 (0.53) CYSLTR1CYSLTR2GRM2MEN1KMT2A
SCHEMBL3158105 0.69 CYSLTR1 (0.55) CYSLTR1CYSLTR2GRM2PPARGPPARA
SCHEMBL1696378 0.68 CYP4F2 (0.76) CYP4F2CYP4A11SLC7A5LOXL2FOLH1
SCHEMBL481005 0.68 CYSLTR1 (0.68) CYSLTR1CYSLTR2GRM2
SCHEMBL2888457 0.68 CYSLTR1 (0.53) CYSLTR1CYSLTR2GRM2MEN1KMT2A
SCHEMBL2891831 0.68 CYSLTR1 (0.53) CYSLTR1CYSLTR2GRM2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2441762-A1 Potentiators of Glutamate Receptors Eli Lilly and Company (US) 2012-04-18 EP disclosed
EP-1817301-B1 POTENTIATORS OF GLUTAMATE RECEPTORS LILLY CO ELI (US) 2012-02-01 EP disclosed
US-7816523-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2010-10-19 US disclosed
US-7803938-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2010-09-28 US disclosed
US-20090318481-A1 Potentiators Of Glutamate Receptors AICHER THOMAS DANIEL 2009-12-24 US disclosed
US-20090318483-A1 Potentiators Of Glutamate Receptors AICHER THOMAS DANIEL 2009-12-24 US disclosed
US-7598423-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2009-10-06 US disclosed
US-20080139505-A1 Potentiators Of Glutamate Receptors ARRAY BIOPHARMA, INC. 2008-06-12 US disclosed
EP-1817301-A1 POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2007-08-15 EP disclosed
WO-2006057870-A1 POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2006-06-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139505-A1 Potentiators Of Glutamate Receptors GRM1, GRIN1, GRM2 CYP4F2 838/4885CYP4A11 1356/4885SLC7A5 642/4885
US-20090318481-A1 Potentiators Of Glutamate Receptors GRIK1, GRIK2, GRIK4 CYP4F2 1546/4885CYP4A11 1088/4885SLC7A5 655/4885
US-20090318483-A1 Potentiators Of Glutamate Receptors GRIK1, GRIK2, GRIK4 CYP4F2 1546/4885CYP4A11 1088/4885SLC7A5 655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.